Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - HC Wainwright increased their Q2 2025 earnings per share estimates for Allogene Therapeutics in a research note issued to investors on Monday, June 2nd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.26) for the quarter, up from their prior forecast of ($0.28). HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics' Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.06) EPS.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28).
A number of other analysts have also weighed in on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research note on Wednesday, May 14th. Piper Sandler reduced their target price on Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Truist Financial dropped their price target on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Canaccord Genuity Group restated a "buy" rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Robert W. Baird reduced their target price on Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.44.
Check Out Our Latest Report on Allogene Therapeutics
Allogene Therapeutics Price Performance
Shares of NASDAQ:ALLO remained flat at $1.29 during trading on Wednesday. The stock had a trading volume of 1,646,951 shares, compared to its average volume of 3,309,248. Allogene Therapeutics has a 1 year low of $0.86 and a 1 year high of $3.78. The firm has a market capitalization of $282.16 million, a PE ratio of -0.83 and a beta of 0.60. The business's 50-day moving average price is $1.34 and its 200-day moving average price is $1.77.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ALLO. Lynx1 Capital Management LP increased its position in shares of Allogene Therapeutics by 75.3% during the 4th quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company's stock worth $23,163,000 after purchasing an additional 4,672,349 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock valued at $8,547,000 after acquiring an additional 3,747,397 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in shares of Allogene Therapeutics in the 4th quarter valued at approximately $7,345,000. Patient Square Capital LP acquired a new position in shares of Allogene Therapeutics in the 4th quarter worth approximately $3,174,000. Finally, Gilead Sciences Inc. acquired a new position in Allogene Therapeutics during the fourth quarter worth $2,464,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Allogene Therapeutics
In other news, CEO David D. Chang sold 46,668 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the sale, the chief executive officer now owns 5,276,569 shares of the company's stock, valued at $10,342,075.24. This represents a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 61,757 shares of company stock worth $115,873 in the last three months. 13.20% of the stock is owned by corporate insiders.
Allogene Therapeutics Company Profile
(
Get Free Report)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Further Reading
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
